In a controversial move to tackle rising obesity rates and boost economic productivity, the UK government is considering offering weight loss injections to the unemployed.
According to NHS data, two in three Britons are classed as overweight or obese, with obesity-related illnesses costing the NHS a whopping £11bn a year. Obesity has also been linked to the development of type 2 diabetes, an area the NHS spends roughly 9% of its entire budget on. Additionally, the cost of our benefits system is predicted to go up by 1/3 over the next five years.
In a subsequent bid to “think differently” about easing pressure on the NHS, the government has announced they will be launching a five-year trial of the weight-loss jab Mounjaro; a weekly injectable pen that helps regulate blood sugar and balance energy levels, reducing appetite and cravings. Initially, the drug will only be given to individuals categorised with severe obesity (BMI over 40) who have at least three obesity-related health conditions. The trial aims to explore whether the medication can boost productivity and help bring more people back to the workforce. Advocating for the drug, health secretary Wes Streeting said: “For all the challenges facing the health of our nation, we have two huge advantages: some of the world’s leading scientific minds, and a National Health Service with enormous potential. If we can combine the two, patients in this country can reap the rewards of the revolution in medical science unfolding before our eyes.”
Amanda Pritchard, the chief executive of the NHS, also voiced her support for the drug, celebrating it as a “game-changer” for public health which could reduce the risk of diabetes, heart attacks, and strokes.
However, not everyone is in agreement. Some point out that the NHS lacks the capacity to oversee such a program effectively, and that addressing the fundamental issues in the NHS, such as chronic underfunding and unequal access to care, is an important factor that isn’t being sufficiently considered. Additionally, there is a concern that the drug may encourage a “dependency culture” where people become reliant upon the jab and do not continue to engage in healthy eating or exercise. Critics also emphasise the need for a more holistic approach to obesity, focusing more on prevention over medication. This includes promoting healthy lifestyles, increasing education, improving food labelling, and making healthy food more accessible.
Initiatives such as the sugar tax, which was introduced in 2018, are celebrated for their efforts to tackle obesity; so, perhaps continuing along this route of pushing food and drink companies to provide healthier products may be the better move forward instead of solely placing the blame on consumers. Other policies, such as Labour’s recent ban on junk food advertisements before the 9pm watershed and proposed measures to provide patients with smartwatches to track health conditions, may also play an important part in tackling the obesity crisis. A crucial aspect often overlooked in this debate is mental health, which is closely intertwined with unemployment.
While this policy may appear promising at first glance, it risks oversimplifying a complex issue. The root of the problem lies in the intricate relationship between inequality, poverty, and poor health. Addressing these fundamental societal challenges should take precedence over medicalization. Relying solely on weight loss injections is akin to applying a superficial fix to a deeper structural problem. A more comprehensive approach that tackles the underlying socio-economic factors is necessary for lasting change.